143 related articles for article (PubMed ID: 31552184)
1. The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis.
Si Z; Zhang S; Yang X; Ding N; Xiang M; Zhu Q; Mao Y; Lv Y; Yu L; Shang H; Xie J; Tian Y
Front Oncol; 2019; 9():866. PubMed ID: 31552184
[No Abstract] [Full Text] [Related]
2. The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Tian Y; Zhang Z; Yang X; Li D; Zhang L; Li Z; Zhang S; Mao Y; Jin C; Zhao Y
Front Oncol; 2020; 10():261. PubMed ID: 32181158
[No Abstract] [Full Text] [Related]
3. Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis.
Zhang C; Zhang S; Xu D; Liu R; Zhu Q; Zhao Y; Mao Y; Tian Y
Cancer Manag Res; 2019; 11():3957-3969. PubMed ID: 31118808
[No Abstract] [Full Text] [Related]
4. Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Tian Y; Gao A; Wen Q; Wang S; Zhang S; Yang X; Su G; Sun Y
Front Immunol; 2020; 11():595655. PubMed ID: 33391266
[TBL] [Abstract][Full Text] [Related]
5. Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis.
Tian Y; Huang A; Tian M; Wang K; Dang Q; Zhang C; Liu H; Zhao J; Yang X; Zhang C; Guo L; Chen F
Medicine (Baltimore); 2022 Sep; 101(36):e30151. PubMed ID: 36086680
[TBL] [Abstract][Full Text] [Related]
6. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
7. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
Deng S; Yang Q; Shu X; Lang J; Lu S
Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
[No Abstract] [Full Text] [Related]
8. The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis.
Li M; Huang L; Ren X; Liu L; Shi Q; Liu L; Wang X; Tian Y; Yu L; Mi F
Medicine (Baltimore); 2020 Oct; 99(42):e22555. PubMed ID: 33080690
[TBL] [Abstract][Full Text] [Related]
9. Immune-related cardiovascular toxicities of PD-1/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis.
Zhang C; Wei F; Ma W; Zhang J
Front Immunol; 2024; 15():1255825. PubMed ID: 38318172
[TBL] [Abstract][Full Text] [Related]
10. Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis.
Xu M; Nie Y; Yang Y; Lu YT; Su Q
Neurologist; 2019 May; 24(3):75-83. PubMed ID: 31045716
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
12. Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment.
Su Q; Zhang X; Shen X; Hou Y; Sun Z; Gao ZH
J Cancer; 2018; 9(9):1614-1622. PubMed ID: 29760800
[No Abstract] [Full Text] [Related]
13. Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens.
Zhao L; Yu J; Wang J; Li H; Che J; Cao B
J Cancer; 2020; 11(1):41-50. PubMed ID: 31892971
[No Abstract] [Full Text] [Related]
14. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
15. Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Liu H; Xu D; Wang W; Sun F; Zhang S; Yang X; Tian Y
Front Oncol; 2020; 10():570080. PubMed ID: 33194659
[No Abstract] [Full Text] [Related]
16. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Lin LL; Lin GF; Luo Q; Chen XQ
Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
[TBL] [Abstract][Full Text] [Related]
17. Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis.
Huang YF; Xie WJ; Fan HY; Du J
Front Oncol; 2019; 9():972. PubMed ID: 31632907
[No Abstract] [Full Text] [Related]
18. Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis.
Tian Y; Zhang C; Dang Q; Wang K; Liu Q; Liu H; Shang H; Zhao J; Xu Y; Wu T; Liu W; Yang X; Safi M
J Oncol; 2022; 2022():4976032. PubMed ID: 35898927
[TBL] [Abstract][Full Text] [Related]
19. The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.
Gu L; Khadaroo PA; Su H; Kong L; Chen L; Wang X; Li X; Zhu H; Zhong X; Pan J; Chen M
BMC Cancer; 2019 Jun; 19(1):559. PubMed ID: 31182049
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
